Advancing DEL-derived small molecule inhibitors of pathological TAU toward preclinical development for alzheimer's disease and tauopathies project summary alzheimer's disease represents one of the…
Active Grant Awarded
- Award ID
- R44AG085856
- Recipient
-
Jillion Therapeutics Inc. UEI KNVYBLASYW88
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,118,025
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 10% complete
- Place of performance
- Brooklyn, NY 11226, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute on Aging awarded Jillion Therapeutics Inc. $1.118025 million under Grant R44AG085856 on September 17, 2026, through the Aging Research program (CFDA 93.866). The award funds a Phase II effort to advance DNA-encoded library (DEL)-derived small molecules that inhibit pathological tau toward preclinical development for Alzheimer's disease and tauopathies. The recipient will confirm and optimize prior hit compounds into lead series using multiple complementary assays, optimize compounds for potency and CNS exposure, and demonstrate in vivo activity against tau pathology and disease progression in tau-driven mouse models of Alzheimer's disease. Testing covers brain penetration, safety, and efficacy. The work culminates in nominating one primary lead candidate and two backup compounds to enter IND-enabling studies. Place of performance is Brooklyn, New York 11226, and the ultimate completion date is May 31, 2028. The program supports biomedical and behavioral research in aging, with particular emphasis on preventing and treating Alzheimer's disease and related dementias.
Description
Advancing DEL-derived small molecule inhibitors of pathological TAU toward preclinical development for alzheimer's disease and tauopathies project summary alzheimer's disease represents one of the most pressing public health challenges, currently affecting more than 6.7 million americans and over 50 million people worldwide, with numbers projected to rise sharply in the coming decades. Despite recent progress with anti-amyloid antibodies, there are still no orally available, disease-modifying treatments that directly target TAU pathology, a central driver of disease progression. Small molecules capable of blocking TAU aggregation and spread would represent a transformative advance for patients, caregivers, and healthcare systems. Jillion therapeutics is addressing this challenge with its proprietary DNA-encoded library (DEL) drug discovery platform, uniquely combined with over 25 years of neuroscience expertise and a focused translational strategy. In phase I, this platform allowed the identification of a large set of novel small-molecule physically binding to TAU, many with properties suitable for further optimization. In phase II, we will advance these HIT candidates by validating prioritized compounds in biochemical and cell-based assays, optimizing HIT families through medicinal chemistry, and testing candidate molecules for brain penetration, safety, and efficacy in well-established tauopathy mouse models. Phase II effort will (1) confirm and optimize hits into lead series using multiple complementary assays, (2) optimize compounds for potency, draggability, and CNS exposure, and (3) demonstrate in vivo activity against TAU pathology and disease progression in TAU-driven mouse models of alzheimer's disease. These studies will culminate in the nomination of one primary lead candidate and two backup compounds to enter IND-enabling studies. This project is designed not only to deliver first-in-class TAU inhibitors but also to establish a generalizable framework for drugging intrinsically disordered proteins, which remain an untapped therapeutic space in neurodegeneration. With strong support from advisors with deep expertise in CNS drug discovery, regulatory planning, and business development, jillion is well positioned to advance these compounds toward clinical testing. The commercial potential is significant, given the urgent unmet need, large patient population, and high healthcare costs associated with alzheimer's disease. In summary, this phase II sbir project will build on successful phase I results to deliver optimized, orally available, brain-penetrant small molecules targeting TAU aggregation. If successful, the work will provide a foundation for a transformative new class of alzheimer's disease therapies, while also creating a scalable discovery engine for other neurodegenerative proteinopathies.
Quick answers
Who received award R44AG085856?
R44AG085856 was awarded to Jillion Therapeutics Inc. by National Institute on Aging (National Institutes of Health) on September 17, 2026.
How much is award R44AG085856 worth?
$1,118,025 has been obligated on R44AG085856.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award